Plasmodium vivax malaria
Plasmodium vivax malaria
Explore linked clinical trials. Standard reference: MONDO:000592118 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Southeast Asia Dose Optimization of Tafenoquine | Disease Attributes, Infections, Mosquito-Borne Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Plasmodium vivax malaria, Recurrence, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Recruiting | Phase 4 | 2026-10-09 | NCT04704999 | |
| An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Recruiting | Phase 3 | 2026-10-01 | NCT06666491 | |
| Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years | Infections, Mosquito-Borne Diseases, Plasmodium falciparum malaria, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 1 | 2026-09-25 | NCT07831226 | |
| Tafenoquine Drug Levels in Small Children | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 2 | 2026-09-22 | NCT07835321 | |
| Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar | Infections, Mosquito-Borne Diseases, Plasmodium falciparum malaria, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Recruiting | Phase 3 | 2026-09-18 | NCT06923592 | |
| This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 2 | 2026-07-30 | NCT07430592 | |
| FocaL Mass Drug Administration for Vivax Malaria Elimination | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Recruiting | Phase 3 | 2026-06-09 | NCT05690841 | |
| Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Not applicable | 2026-04-16 | NCT07533136 | |
| Tafenoquine and ACTs (TADORE- Plus) | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 4 | 2026-03-18 | NCT07060794 | |
| Postpartum 8-aminoquinoline Breast Milk Study | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 2 / Phase 3 | 2026-03-18 | NCT07060404 | |
| Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Recruiting | Phase 4 | 2026-03-18 | NCT07052162 | |
| Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, G6PD deficiency, Hemic and Lymphatic Diseases, Infections, Mosquito-Borne Diseases, Nutritional and Metabolic Diseases, Plasmodium vivax malaria, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, malaria, metabolic disease, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Recruiting | Phase 4 | 2026-03-12 | NCT07468513 | |
| Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 4 | 2026-02-12 | NCT07403643 | |
| Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 2 | 2026-01-28 | NCT07373301 | |
| Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax." | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 1 | 2025-09-15 | NCT07172724 | |
| A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Recruiting | Phase 3 | 2025-07-18 | NCT06148792 | |
| ACT vs CQ With Tafenoquine for P. Vivax Mono-infection | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Recruiting | Phase 4 | 2025-05-16 | NCT05788094 | |
| Plasmodium Immunotherapy for Advanced Ovarian Cancer | Infections, Mosquito-Borne Diseases, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 2 / Phase 3 | 2024-07-22 | NCT05924776 |